These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 36685530)
1. CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis. Li J; Li H; Wang Y; Zhao X; Wang S; Li L Front Immunol; 2022; 13():1071219. PubMed ID: 36685530 [TBL] [Abstract][Full Text] [Related]
2. Clinical features of 28 cases of anti Feng J; Li J; Xie Y; Lü Y; Bi F; Zhou J Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):386-396. PubMed ID: 37164922 [TBL] [Abstract][Full Text] [Related]
3. Clinical features of anti-leucine-rich glioma-inactivated 1 encephalitis in northeast China. Zhao Q; Sun L; Zhao D; Chen Y; Li M; Lu Y; Li G; Lin W Clin Neurol Neurosurg; 2021 Apr; 203():106542. PubMed ID: 33706063 [TBL] [Abstract][Full Text] [Related]
4. Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2. Murayama A; Sugaya K; Hara M; Kawazoe T; Tobisawa S; Nakajima H; Takahashi K Intern Med; 2023 Jun; 62(11):1659-1663. PubMed ID: 36223927 [TBL] [Abstract][Full Text] [Related]
5. A case of pediatric anti-leucine-rich glioma inactivated 1 encephalitis with faciobrachial dystonic seizure. Jang S; Kim SY; Kim WJ; Chae JH; Kim KJ; Lim BC Brain Dev; 2023 Jun; 45(6):348-353. PubMed ID: 36858863 [TBL] [Abstract][Full Text] [Related]
6. [Clinical analysis of 9 cases with Anti-leucine-rich glioma inactivated 1 protein antibody associated limbic encephalitis]. Zhang YX; Yang HL; Wu YY; Wang CC; Gao XY; Shi YY; Liu HQ; Huang Y; Zhang JW Zhonghua Yi Xue Za Zhi; 2017 May; 97(17):1295-1298. PubMed ID: 28482428 [No Abstract] [Full Text] [Related]
7. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study. Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133 [TBL] [Abstract][Full Text] [Related]
8. [Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis]. Li JM; Ma XR; Peng T; Li JH; Lu H Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1947-1951. PubMed ID: 32629594 [No Abstract] [Full Text] [Related]
9. Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspartate receptor encephalitis. Zhao J; Wang C; Zhang Y; Sun R; Wang H; Li G; Zhang J J Neuroimmunol; 2019 Sep; 334():577005. PubMed ID: 31310926 [TBL] [Abstract][Full Text] [Related]
10. What Is Different about Teratoma-Associated Anti-LGI1 Encephalitis? A Long-Term Clinical and Neuroimaging Case Series. Li C; Cai HB; Zhao X; Xi XC; Zhou Q; Luo HY; Tang ZP; Kang HC; Kirsch HE Eur Neurol; 2022; 85(6):437-445. PubMed ID: 35896086 [TBL] [Abstract][Full Text] [Related]
11. A Case of Anti-Leucine-Rich Glioma-Inactivated Protein 1 (Anti-LGI1) Limbic Encephalitis With New-Onset Panic Attacks. Coleman B; Sawhney K; LaPenna P Cureus; 2024 Apr; 16(4):e58406. PubMed ID: 38756253 [TBL] [Abstract][Full Text] [Related]
12. Origin and significance of leucine-rich glioma-inactivated 1 antibodies in cerebrospinal fluid. Zhang F; Zhou H; Yi Y; Li N; Liu M; Shen H; Guo Y; Wang J Neurol Sci; 2024 Sep; 45(9):4493-4500. PubMed ID: 38551680 [TBL] [Abstract][Full Text] [Related]
13. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study. Muñoz-Lopetegi A; Guasp M; Prades L; Martínez-Hernández E; Rosa-Justícia M; Patricio V; Armangué T; Rami L; Borràs R; Castro-Fornieles J; Compte A; Gaig C; Santamaria J; Dalmau J; Lancet Neurol; 2024 Mar; 23(3):256-266. PubMed ID: 38365378 [TBL] [Abstract][Full Text] [Related]
14. Autoimmune encephalitis related to LGI1 antibodies with negative MRI study: Description of two cases. Lian X; Zheng K; Chen W; Li D; Xue F; Wang G Med Clin (Barc); 2024 Jan; 162(1):35-38. PubMed ID: 37517931 [TBL] [Abstract][Full Text] [Related]
15. CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study. Nissen MS; Ryding M; Nilsson AC; Madsen JS; Olsen DA; Halekoh U; Lydolph M; Illes Z; Blaabjerg M Front Immunol; 2021; 12():719432. PubMed ID: 34975832 [TBL] [Abstract][Full Text] [Related]
16. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis. Huang X; Fan C; Gao L; Li L; Ye J; Shen H J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327 [TBL] [Abstract][Full Text] [Related]
17. Predicting the functional outcomes of anti-LGI1 encephalitis using a random forest model. Li G; Liu X; Wang M; Yu T; Ren J; Wang Q Acta Neurol Scand; 2022 Aug; 146(2):137-143. PubMed ID: 35373330 [TBL] [Abstract][Full Text] [Related]
18. Agrypnia excitata as the main feature in anti-leucine-rich glioma-inactivated 1 encephalitis: a detailed clinical and polysomnographic semiological analysis. Piffer S; Cantalupo G; Filipponi S; Poretto V; Pellegrini M; Tanel R; Buganza M; Giometto B Eur J Neurol; 2022 Mar; 29(3):890-894. PubMed ID: 34679240 [TBL] [Abstract][Full Text] [Related]
19. Autoimmune parkinsonism with faciobrachiocrural dystonic seizures: a new phenotype of leucine-rich glioma-inactivated 1 (LGI1) autoimmunity. Sasikumar S; Vincent J; Gopinath S; Nambiar V; Umesh SU; Kannoth S; Antony D; Mathai A; Anandakuttan A Acta Neurol Belg; 2022 Oct; 122(5):1323-1328. PubMed ID: 35851655 [TBL] [Abstract][Full Text] [Related]
20. Comparing clinical features, severity and prognosis of autoimmune encephalitis and with and without oligoclonal bands. Xue H; Guo X; Jiang Y; Qin L; Wang X; Xu J; Zuo S; Liu Q; Li W Front Neurol; 2023; 14():1281276. PubMed ID: 38249729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]